TIL-based Therapies 2021-2030 by Roots Analysis

Category: Health

Roots Analysis has announced the addition of “TIL-based Therapies Market, 2021-2030” report to its list of offerings. Given the frequently reported inadequacies of conventional cancer therapies and the growing need for personalized medicine, there is a marked surge in the demand for TIL-based therapies. In addition, the clinical success in this domain is likely to draw in investments that will support ongoing and anticipated therapy development initiatives. To order this 255+ page report, which features 90+ figures and 100+ tables, please visit https://www.rootsanalysis.com/reports/til-therapies-market.html Key Market Insights Over 80 TIL-based therapies are currently under development Close to 55% of the aforementioned candidates are being evaluated in clinical stages (phase I/II and above), while more than 20% therapies are in preclinical and discovery stages. Examples of late-stage clinical candidates include CCRT+TIL, Lifileucel, LTX-315 and TILs, and IOV-2001 and LN-145. More than 80% pipeline candidates are presently being developed to target solid tumors T-cell immunotherapy developers were observed to be primarily focused on the treatment of different oncological indications. It is worth noting that 17% pipeline candidates are being developed for the treatment of both hematological and solid tumors.